(Q30582030)

25 June 2017

title

Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer (English)

1 reference

triple-negative breast cancer

25 June 2017

1 reference

1 reference

R Calero

6

0 references

Azucena Esparís-Ogando

object named as

A Esparís-Ogando

2

0 references

Atanasio Pandiella

8

object named as

A Pandiella

1 reference

25 June 2017

1

J C Montero

1 reference

25 June 2017

M F Re-Louhau

3

1 reference

25 June 2017

S Seoane

4

1 reference

25 June 2017

M Abad

5

1 reference

25 June 2017

A Ocaña

7

1 reference

25 June 2017

language of work or name

English

0 references

publication date

17 December 2012

1 reference

25 June 2017

1 reference

25 June 2017

volume

33

1 reference

25 June 2017

issue

2

1 reference

25 June 2017

page(s)

148-156

1 reference

Triple-negative breast cancer: therapeutic options

25 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Triple-negative breast cancer: disease entity or title of convenience?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Dissecting the heterogeneity of triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Triple-negative breast cancer: clinical features and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Tyrosine phosphorylation: thirty years and counting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Targeted therapies for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Preclinical development of molecular-targeted agents for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

mTOR signaling at a glance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Multisite phosphorylation of Erk5 in mitosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Triple-negative breast cancer: an unmet medical need

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling-competent truncated forms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.572

31 March 2020

Identifiers

DOI

10.1038/ONC.2012.572

1 reference

Dimensions Publication ID

25 June 2017

1031559985

0 references

1 reference